NEWARK, Calif., May 13, 2015 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at two healthcare conferences in May.
The 2015 Bank of America Merrill Lynch Healthcare Conference in Las Vegas. The presentation at the Bank of America Merrill Lynch conference is scheduled for 1:00 pm EDT (10:00 am PDT) Thursday May 14, 2015.
The UBS 2015 Global Healthcare Conference in New York City. The presentation at the UBS conference is scheduled for 8:30 am EDT (5:30 am PDT) Wednesday May 20, 2015.
Both presentations will be webcast, and the webcasts can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcasts will be archived for 30 days on the company’s website.
About Depomed
Depomed is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders. Our NUCYNTA® franchise includes NUCYNTA® ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment, and NUCYNTA® (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia. CAMBIA® (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks with or without aura in adults (18 years of age or older). Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain in adults. Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Gralise and various partner product candidates are formulated with Depomed’s proven, proprietary Acuform® drug delivery technology. Additional information about Depomed may be found at www.depomed.com.
INVESTOR CONTACT:
August J. Moretti
Depomed, Inc. 510.744.8000
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/depomed-to-present-at-healthcare-conferences-in-may-300082916.html
SOURCE Depomed, Inc.
Help employers find you! Check out all the jobs and post your resume.
